Aug 19, 2026
Study found a dose-response pattern, with the highest odds within 500 feet
Written by Margarida Maia, PhD | Aug. 11, 2026
- Living near dry cleaners was associated with higher Parkinson’s odds in adults age 67 and older.
- The association was strongest among those living within about 500 feet, but the study did not establish that long-term TCE exposure caused the higher odds.
- The researchers said more study is needed to better understand environmental exposures and the regional differences seen in Parkinson’s risk.
People age 67 and older who lived closer to dry cleaners had higher odds of Parkinson’s disease than those who lived farther away, according to a U.S. study. The researchers said exposure to dry-cleaning chemicals such as trichloroethylene (TCE) could help explain the association, but more research is needed.
The highest odds were among those living within 500 feet of a dry cleaner, with particularly strong links in the Dallas–Fort Worth area, parts of the South, the Detroit area, and the New York City metropolitan area extending into New Jersey.
Dry-cleaning chemicals may contribute to Parkinson’s risk
“Our findings suggest that chemicals used in dry cleaning may contaminate nearby neighborhoods and contribute to [Parkinson’s] risk,” the researchers wrote in “Nationwide association between proximity to dry cleaners and risk of Parkinson’s disease,” published in npj Parkinson’s Disease.
Breathing certain chemicals may fuel the buildup of protein clumps called Lewy bodies in the brain. Lewy bodies can damage nerve cells and lead to symptoms of Parkinson’s. One chemical, TCE, a solvent used in dry cleaning, can persist in soil, air, and groundwater for many years and has been linked to an increased risk of Parkinson’s. The researchers noted, however, that they could not specifically test measured TCE levels in relation to Parkinson’s risk in this study.
This study examined whether living near dry cleaners was associated with Parkinson’s. It included U.S. Medicare beneficiaries age 67 and older who lived within five miles of a dry cleaner. The researchers compared 180,982 people newly diagnosed with Parkinson’s with more than 18.8 million people who did not have the disease.
Parkinson’s was more common in older adults and men — patterns already well known from previous research. However, the closer people lived to a dry cleaner, the higher their odds of Parkinson’s. Those living within 500 feet of a dry cleaner had 14% higher odds than those living four to five miles away.
The strongest link was found for Parkinson’s with gait disturbance or postural instability, which can cause problems with walking and maintaining balance. People living within about 500 feet of a dry cleaner had 23% higher odds of Parkinson’s with these gait problems than those living four to five miles away.
Aug 18, 2026
In trial, treatment showed benefits in those with early-onset disease
Written by Margarida Maia, PhD | Aug. 10, 2026
- The U.S. Food and Drug Administration has awarded fast track status to an experimental stem cell therapy for Parkinson's disease.
- XS411 is a ready-to-use therapy designed to replace lost dopamine-producing nerve cells and restore neurological function in patients.
- The treatment candidate is now being tested for early Parkinson's in a clinical trial in China.
An off-the-shelf, or ready to use, stem cell therapy that’s designed to replace the nerve cells lost in Parkinson’s disease and restore neurological function has been put on a developmental fast track by the U.S. Food and Drug Administration (FDA).
The FDA awarded fast track status — a designation that could mean a faster pathway through regulatory review if clinical data are positive — to XS411, being developed by China-based Xellsmart. Clinical trials have already been cleared in both China and the U.S. to test the injection therapy.
According to the developer, a Phase 1/2 study (NCT07166757) in China has shown benefits with the therapy’s use in people with early-onset Parkinson’s.
In a company press release, Xellsmart called the new U.S. designation a “key milestone for [the] global clinical development” of XS411. Such status offers more frequent communication with the FDA and access to rolling review, which means parts of the data can be submitted as they become available rather than waiting until the full package is ready before filing for approval.
Aug 17, 2026
27 Jul 2026 American Medical Journal - Neurology - Author: Katrina Thornber
Key Summary:
- A Danish cohort study of 3,103,577 people examined road traffic noise and Parkinson disease risk.
- Higher noise exposure was linked to increased PD risk (HR 1.03–1.06 across models).
- A quiet facade was linked to lower risk, supporting noise mitigation strategies.
A LARGE Danish cohort study has revealed that long-term exposure to road traffic noise is associated with a higher risk of Parkinson disease, though having a quiet facade at home appeared to reduce this added risk.
Road Traffic Noise as a Potential Risk Factor for Parkinson Disease
Transportation noise has been proposed as a potential risk factor for Parkinson disease, but epidemiological evidence remained limited and inconsistent. Long-term road traffic noise exposure has increasingly drawn interest as a modifiable environmental factor, yet its link to Parkinson disease risk had not been comprehensively established.
Danish Nationwide Cohort Study Design
Researchers conducted a Danish nationwide prospective cohort study with follow-up from 2000 to 2017, including residents aged 40 years and older. Using complete residential address histories from 1990 onward, the study assessed 10-year time-weighted exposure to road traffic noise at the most and least exposed facades of each home. Of 3,542,488 eligible individuals, 438,911 were excluded due to prevalent Parkinson disease, incomplete address history, or missing covariates, leaving 3,103,577 participants (mean baseline age 50.9 years; 51.2% female). Cases were identified via the National Patient Register and analysed using Cox proportional hazards models adjusted for sociodemographic, air pollution, and green space covariates.
Aug 14, 2026
Alpha-synuclein, inflammation, nerve health markers lowered with risvodetinib
Written by Patricia Inácio, PhD | Aug. 7, 2026
- Risvodetinib is an oral experimental therapy being developed to treat Parkinson’s disease and address underlying cellular damage.
- A 12-week Phase 2 trial showed the oral therapy significantly reduced multiple disease-related biomarkers in patients.
- The markers reflected processes associated with nerve cell degeneration, mitochondrial health, and neuroinflammation.
Risvodetinib, an oral therapy Abli Therapeutics is developing for people with Parkinson’s disease, reduced multiple disease-related biomarkers, the company announced.
The findings come from an expanded analysis of the 201 Phase 2 study (NCT05424276), which enrolled patients with bradykinesia (slowed movement), a hallmark symptom of Parkinson’s.
The trial tested once-daily risvodetinib against a placebo for three months in people with early, untreated Parkinson’s. Earlier results suggested that risvodetinib stabilized disease status and severity, and improved patient quality of life.
The new biomarker analysis involved 7,300 individual measures from as many as 80 participants in the 201 study. It expanded on earlier skin-biopsy findings by adding longitudinal blood measures from 80 participants and cerebrospinal fluid (CSF, the fluid surrounding the brain and spinal cord) measures from six participants, with samples collected at the start and end of the trial.
Eleven disease-related biomarkers measured in tissue, blood, and CSF responded to risvodetinib, according to a company press release, The analysis “has revealed surprising information, both about the underlying processes of disease and how patients respond to risvodetinib treatment,” said Milton Werner, Abli’s chairman and CEO.
Aug 13, 2026
Finnish health register data tracks air quality across decades
Written by Marisa Horak, MS | Aug. 6, 2026
- Long-term exposure to ozone air pollution may increase the risk of developing Parkinson’s disease.
- Animal studies suggest ozone exposure can trigger brain damage similar to Parkinson's pathology.
- Further research using reliable methodologies is needed to confirm the association.
Long-term exposure to ozone, a form of air pollution, may increase the risk of developing Parkinson’s disease, according to a new study from Finland.
“In this nationwide register study of long-term exposure to gaseous air pollutants and [Parkinson’s] risk, we observed a borderline statistically significant increased risk for [Parkinson’s] after long-term exposure to [ozone],” researchers wrote.
The study, “Long-term exposure to six gaseous air pollutants and risk of Parkinson’s Disease,” was published in npj Parkinson’s Disease.
Parkinson’s risk elevated among those with higher ozone exposure
The causes of Parkinson’s are not fully understood. the disease’s development may be influenced by many different risk factors. An emerging body of evidence suggests that some types of air pollution may increase Parkinson’s risk, but these associations have not been proven definitively.
Ozone is a type of air pollution that forms as a result of reactions between chemicals made from industry and fossil fuel combustion. In previous studies, ozone has been identified as one of the main air pollutants that may influence the risk of Parkinson’s disease.
Recent Comments